Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851002 | 0.79 | CA12 (0.56) | RXRARXRBCA12CA1CA2 | |
| SCHEMBL7530437 | 0.79 | FFAR4 (0.42) | FFAR4POLB | |
| SCHEMBL1852479 | 0.77 | SLC7A5 (0.49) | RXRACA12CA1CA2CA9 | |
| SCHEMBL7526137 | 0.77 | ADRB3 (0.46) | RXRARXRBRXRG | |
| SCHEMBL508555 | 0.74 | CA1 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30625924 | 0.72 | KMT2A (0.52) | RXRARXRBSLC7A5 | |
| SCHEMBL20241781 | 0.71 | SLC7A5 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15876193 | 0.71 | SLC7A5 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28992722 | 0.70 | LOXL2 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL17230483 | 0.70 | KMT2A (0.59) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486141-B2 | TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| EP-1244677-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | disclosed |
| WO-2001046203-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PTPRO, PPM1B, PTPA | FFAR4 1613/4885RXRA 2868/4885RXRB 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.